Letter to the editor: The perspective of GLP-1/GLP-2 receptors against NASH via diverse regulation
- PMID: 35753059
- DOI: 10.1002/hep.32636
Letter to the editor: The perspective of GLP-1/GLP-2 receptors against NASH via diverse regulation
Comment on
-
A GLP-1/GLP-2 receptor dual agonist to treat NASH: Targeting the gut-liver axis and microbiome.Hepatology. 2022 Jun;75(6):1523-1538. doi: 10.1002/hep.32235. Epub 2021 Dec 18. Hepatology. 2022. PMID: 34773257
References
REFERENCES
-
- Kim ER, Park JS, Kim JH, Oh JY, Oh IJ, Choi DH, et al. A GLP-1/GLP-2 receptor dual agonist to treat NASH: targeting the gut-liver axis and microbiome. Hepatology. 2022;75:1523-38.
-
- Madsen MSA, Holm JB, Pallejà A, Wismann P, Fabricius K, Rigbolt K, et al. Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice. Sci Rep. 2019;9:15582.
-
- Iacobellis G, Camarena V, Sant DW, Wang G. Human epicardial fat expresses glucagon-like peptide 1 and 2 receptors genes. Horm Metab Res. 2017;49:625-30.
-
- Stahel P, Xiao C, Nahmias A, Tian L, Lewis GF. Multi-organ coordination of lipoprotein secretion by hormones, nutrients and neural networks. Endocr Rev. 2021;42:815-38.
-
- Simon MC, Strassburger K, Nowotny B, Kolb H, Nowotny P, Burkart V, et al. Intake of Lactobacillus reuteri improves incretin and insulin secretion in glucose-tolerant humans: a proof of concept. Diabetes Care. 2015;38:1827-34.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical